HETEROCYCLES, Vol. 68, No. 11, 2006, pp. 2269 - 2283. © The Japan Institute of Heterocyclic Chemistry Received, 14th July, 2006, Accepted, 19th September, 2006, Published online, 22nd September, 2006. COM-06-10842

# **SYNTHESIS OF NOVEL 1,3,4-OXADIAZIN-5(***6H***)-ONES AND 2-HYDROXYMETHYL-1,3,4-OXADIAZOLES**

#### **Agnieszka Kudelko\* and Wojciech Zieliński**

Department of Organic Technology and Petrochemistry, Silesian University of Technology, Ul. Krzywoustego 4, PL-44101 Gliwice, Poland

E-mail: Agnieszka.Kudelko@polsl.pl

**Abstract** – Reactions of  $\alpha$ -hydroxyacid hydrazides (benzilic,  $R$ - and *S*-mandelic) and triethyl orthoesters (orthoformate, orthoacetate, orthopropionate, orthobenzoate) in glacial acetic acid resulted in two groups of heterocyclic compounds, derivatives of 6-phenyl-1,3,4-oxadiazin-5-(*6H*)-one and 2-hydroxymethyl-1,3,4-oxadiazole. Their structures were confirmed by typical spectroscopic methods and X-Ray analysis. Spectral characteristic of the compounds and attempts to elucidate the mechanism are discussed.

### **INTRODUCTION**

1,3,4-Oxadiazines belong to a group of heterocyclic compounds that exhibit a wide range of biological activities.<sup>1</sup> A lot of compounds containing a fused  $1,3,4$ -oxadiazine arrangement demonstrate strong antiviral and antibacterial activities.<sup>2-5</sup> They also inhibit some metabolic processes proceeding in the presence of enzyms such as: *monoamine oxidaze*, *lipoxygenaze* or *cycloxygenaze*. 6,7 Cardiotonic and antihypertensive activities have been reported for 2-substituted-1,3,4-oxadiazin-5(6H)-ones.<sup>8,9</sup> They are also applied in agriculture as pesticides, acaricides and nematocides.<sup>10,11</sup> Working earlier on the synthesis of 4-acylamino-1,2,4-triazoles in the reactions of α-hydroxycarboxylic acid hydrazides and orthoesters some single 1,3,4-oxadiazin-5( $6H$ )-one derivatives have been obtained.<sup>12</sup> Inspired by the biological activity of such compounds, we have attempted to modify conditions properly in order to produce them. This area seemed to be also very interesting due to the fact that 1,3,4-oxadiazin-5(*6H*)-ones have not been synthesized this way so far. The most popular method to synthesize 1,3,4-oxadiazine arrangement uses *N*-substituted alkyl- or arylcarboxylic acid hydrazides as substrates that undergo cyclization in acidic or

basic medium.13-15 The others involve azodicarbonyl compounds and methoxyethylene derivatives in *Diels-Alder* reactions.<sup>16,17</sup> Few cases of four-<sup>18</sup> and five-membered ring<sup>19</sup> expansions yielding such 1,3,4-oxadiazines have been also reported. The aim of our study was to synthesize some novel 1,3,4-oxadiazin-5(*6H*)-one derivatives starting from α-hydroxycarboxylic acid hydrazides and orthoesters.

# **RESULTS AND DISCUSSION**

Our earlier research<sup>12</sup> on the reactions of α-hydroxycarboxylic acid hydrazides with the excess of orthoesters revealed that 1-(alkanecarbonyl)-2-ethoxymethylenehydrazines (**2**, Scheme 1) were the main products. The introduction of ethanol and acetic acid changed the course of the reaction and more extended *N,N'*-bis(alkanecarbonylamino)formamidines (**4**) were produced. They underwent the further cyclization to the final heterocyclic compounds, the derivatives of 4-acylamino-1,2,4-triazoles (**5**, Scheme 1). Those reactions where triethyl ortoformate were applied in, we separated two different products: acyclic intermediate (**2**) and 1,3,4-oxadiazin-5(*6H*)-ones (**3**).



# Scheme 1

Considering this fact we came to the conclusion that it was the acidic hydrogen atom in triethyl ortoformate molecule responsible for the cyclization of the intermediate (**2**) to 1,3,4-oxadiazin-5(*6H*)–one (**3**). If such foundation holds, the introduction of acidic solvent to the reactions of the rest of orthoesters ( $R^2$  = Me, Et, Ph) should lead to the same group compounds (**3**). Following this idea, α-hydroxyacid hydrazies (**1**) were subjected to heating with the excess of orthoesters in the acetic acid medium (Scheme 2). The first series concerned the reactions of benzilic acid hydrazide with orthoesters  $(R^2 = H, Me, Et, Ph)$ . This time no



Scheme 2

The yields of 1,3,4-oxadiazin-5(*6H*)-ones (**3a-c**) fairly vary from 10-65% (Table 1) and depend on the kind of substituent  $R^2$  contributed by orthoester.

Table		Characteristics		6,6-diphenyl-1,3,4-oxadiazin-5 $(6H)$ -ones	$(3a-c)$	and	
2-(1,1-diphenyl-1-hydroxymethyl)-1,3,4-oxadiazoles (6a-d) derived from benzilic acid hydrazide.							



a) Yield in respect to the original hydrazide.

The more bulky the substituent  $R^2$  is, the lower 1,3,4-oxadiazin-5(6H)-one yield is resulted and finally in the case of triethyl orthobenzoate ( $R^2 = Ph$ ) we did not obtained any six-membered derivative but only the five-membered one. Four derivatives of 2-(1,1-diphenyl-1-hydroxymethyl)-1,3,4-oxadiazole (**6a-d**) were simultaneously obtained with much better yields (68-85%, Table 1). Contrary to the six-membered derivatives of **3**, we observed the reversed trend in the case of **6a-d**. The yields of 1,3,4-oxadiazoles depend on electronic effects of the substituents  $R^2$  attached to the ethoxymethylene carbon atom. The highest yield

was obtained in the case of 6d  $(R^2 = Ph)$  due to the fact that phenyl group is the electron withdrawing one and it stabilizes the tautomeric structure **2b** (Scheme 3) responsible for the formation of 1,3,4-oxadiazoles. We have also prepared two enantiomeric *S*- and *R*- hydrazides of mandelic acid and subjected them to the heating with the excess of orthoesters in the conditions mentioned above. The reactions have again resulted in two products but this time the yields of 1,3,4-oxadiazin-5(*6H*)-ones (**3e-h**, **3i-l**) increased a little at the cost of 1,3,4-oxadiazoles (**6e-h**, **6i-l**) comparing to the series based on benzilic acid hydrazide (Tables 2, 3). The structures of products were confirmed by means of elemental analyses, typical spectroscopic methods (UV, MS, <sup>1</sup>H- and <sup>13</sup>C-NMR) and X-Ray analysis. Optical rotations [ $\alpha$ ] were also determined for products (**3e-l**) and (**6e-l**) obtained from optically active *S*- and *R*-mandelic acid hydrazides.

Table 2. Characteristics of 6-phenyl-1,3,4-oxadiazin-5(*6H*)-ones (**3e-h**) and 2-(1-hydroxy-1-phenylmethyl)-1,3,4-oxadiazoles (**6e-h**) derived from *S*(+)-mandelic acid hydrazide.

Product	R <sup>1</sup>	$R^2$	Yield <sup>a)</sup> $[\%]$	$mp [^{\circ}C]$	$R_f$	$\overline{[\alpha]_D}^{20}$ $(MeOH, C=1.0)$
3e	H	H	50	129-132	0.54	$-203.9$
6e	H	H	45	$\overline{\phantom{a}}$	0.40	$+4.2$
3f	H	Me	45	106-108	0.40	$-117.8$
6f	H	Me	50	126-128	0.32	$+5.7$
3g	H	Et	24	$\overline{\phantom{a}}$	0.50	$-50.5$
6g	H	Et	64	69-71	0.32	$+18.5$
3 <sub>h</sub>	H	Ph	12	84-85	0.12	$+15.7$
6h	H	Ph	85	148-149	0.45	$+60.2$

a) Yield in respect to the original hydrazide.

Considering the optical rotations in two series of 2-(1-hydroxy-1-phenylmethyl)-1,3,4-oxadiazoles (**6e-h**, **6i-l**) one should noticed that four pair of enantiomers were obtained. The absolute configuration at the asymmetric carbon atom is hold because such atom is not involved in the formation of **6**. We assumed, that the intermediate 1-(alkanecarbonyl)-2-ethoxymethylenehydrazine (**2**) played the essential role in the formation of both heterocyclic products. The hydrazide (**2a**) may occur in another tautomeric form hydroxyhydrazone (**2b**), where the second methylene carbon atom appears (Scheme 3). It is substituted with the hydroxy group that attacks *N*-ethoxymethylene carbon atom yielding 1,3,4-oxadiazole arrangement.



Scheme 3

Table 3. Characteristics of 6-phenyl-1,3,4-oxadiazin-5(*6H*)-ones (**3i-l**) and 2-(1-hydroxy-1-phenylmethyl)-1,3,4-oxadiazoles (**6i-l**) derived from *R*(-)-mandelic acid hydrazide.

Product	R <sup>T</sup>	$R^2$	Yield <sup>a)</sup> $\lceil\% \rceil$	$mp [^{\circ}C]$	$R_f$	$\overline{[\alpha]_D}^{20}$ $(MeOH, C=1.0)$
3i	H	H	60	129-131	0.54	$+97.4$
6i	H	H	32	$\blacksquare$	0.40	$-4.3$
3j	H	Me	50	103-105	0.40	$+119.3^{b}$
6j	H	Me	45	126-127	0.32	$-5.7$
3k	H	Et	30	$\overline{\phantom{a}}$	0.50	$+48.4$
6k	H	Et	65	68-70	0.32	$-18.6$
3 <sub>l</sub>	H	Ph	10	83-84	0.12	$-28.1$
<b>61</b>	H	Ph	84	148-149	0.45	$-60.4$

a) Yield in respect to the original hydrazide.

b) 6*R* absolute configuration according to X-Ray analysis.

The measurements of the optical rotation for 1,3,4-oxadiazin-5(*6H*)-ones (**3e-h**, **3i-l**) derived from two enantiomeric *S*- and *R*-mandelic acid hydrazides showed that the mixtures of enantiomers are formed. In contrast to 1,3,4-oxadiazoles, the asymmetric carbon atom in the intermediate (**2**) is directly involved in the formation of 1,3,4-oxadiazin-5( $6H$ )-one (3). If such a product arised from the attack of the α-hydroxy group at the ethoxymethylene carbon atom in the intermediate (**2a**), the absolute cofiguration would be hold and one would obtained pure enantiomers (Scheme 4, path A). The X-Ray investigation of 2-methyl-5-phenyl-1,3,4-oxadiazin-5(*6H*)-one (**3j**) obtained in the reaction of *R*-mandelic acid hydrazide and triethyl ortoacetate revealed that the molecule has the same absolute *R* configuration at C6 like starting hydrazide. It proves that the product is really resulted in this way. However, the differences in measured values  $(R^2 = H, Ph)$  suggest that the formation of **3** could partly proceed another path through the stable benzyl cation (Scheme 4, path B). The asymmetry at carbon in hydrazide (**2**) is lost and after the substitution with the water molecule and further cyclization two optical isomers are formed.



Scheme 4

As mentioned before, the structure of 2-methyl-6-phenyl-1,3,4-oxadiazin-5(*6H*)-one (**3j**) was confirmed by X-Ray analysis. ORTEP<sup>20</sup> drawing of 3*j* is shown in Figure 1. There are two independent molecules A and B in asymmetric part of the unit cell of **3j**.



Figure 1. ORTEP drawing of **3j** showing 30 % probability displacement ellipsoids.

These molecules, having the same absolute configuration of C6 identified as *R* and very similar geometry (Table 4), differ in conformation described by torsion angle O1–C6–C11–C12 of -34.6(2)<sup>o</sup> and 92.5(2)<sup>o</sup> for A and B, respectively. The oxadiazine rings both adopt diplanar conformation, with asymmetry parameters  $\Delta C_2^{N3A,N4A} = 2.2(3)^{\circ}$  and  $\Delta C_2^{N3B,N4B} = 0.8(3)^{\circ}$ ,<sup>21</sup> and two torsion angles close to 0<sup>o</sup> [O1–C2–N3–N4 of -0.3(3)<sup>o</sup> and  $0.0(3)$ <sup>o</sup> and N3–N4–C5–C6 of  $1.1(2)$ <sup>o</sup> and -0.2(3)<sup>o</sup>] in molecules A and B, respectively.

 $\text{Bond } [\AA]$   $A$   $B$   $\text{Angle } [^{\circ}]$ ] A B O1-C2 1.347(3) 1.348(3) C2-O1-C6 118.79(14) 118.74(15) O1-C6 1.439(2) 1.440(3) C2-N3-N4 116.67(18) 116.56(19) O8-C5 1.215(2) 1.220(2) C5-N4-N3 125.40(15) 125.43(17) N3-C2 1.261(2) 1.260(3) N3-C2-O1 126.34(18) 126.30(18) N3-N4 1.392(2) 1.395(2) N3-C2-C7 121.1(2) 120.7(3) N4-C5 1.330(3) 1.324(3) O1-C2-C7 112.6(2) 112.9(2) C2-C7 1.489(3) 1.490(3) O8-C5-N4 123.73(18) 123.52(18) C5-C6 1.519(3) 1.512(3) O8-C5-C6 120.06(19) 120.06(19) C6-C11 1.512(2) 1.508(3) N4-C5-C6 116.21(15) 116.42(16)  $O1-C6-C11$  111.84(15) 111.34(16) O1-C6-C5 113.05(16) 112.97(17) C11-C6-C5 110.01(14) 111.89(15)

Table 4. Selected bond distances  $[\hat{A}]$  and angles  $[\text{°}]$  for **3j** in molecules A and B.

In the crystal structure of **3j** (Figure 2), the molecules related by  $2<sub>1</sub>$  axes are joined in molecular chains parallel to Y crystallographic axis *via* N4–H4...O8 classical intermolecular hydrogen bonds. Additionally, the molecular packing in the crystal is influenced by the presence of the three-dimensional network of the weak intermolecular C–H...X ( $X = N$ , O ) hydrogen bonds. The geometry and symmetry codes of all intermolecular interactions are presented in Table 5.



Figure 2. Packing diagram of the molecule (**3j**). The hydrogen bonds are indicated by broken lines.

Type	Symmetry	$D-H$	HA	DA	$D-HA$		
	code	$\rm{[\AA]}$	[A]	[A]	$[^{\circ}]$		
N4A-H4AO8A	2655	0.84(3)	2.00(3)	2.826(2)	169(3)		
N4B-H4BO8B	2656	0.78(3)	2.07(3)	2.850(2)	173(3)		
C6A-H6AN3A	1545	0.97(3)	2.46(3)	3.412(3)	168(2)		
$C6B-H6BN3B$	1545	1.05(3)	2.44(3)	3.478(3)	169(2)		
C14B-H14BO8B	1455	1.03(3)	2.59(3)	3.542(3)	153(3)		
C15B-H15BO8B	2556	0.97(4)	2.59(4)	3.521(3)	162(3)		
$2655 = 1-x$ , $\frac{1}{2}+y$ , -z;			$1545 = x, -1+y, z;$		$2656 = 1-x$ , $\frac{1}{2}+y$ , 1-z;		
$1455 = -1+x, y, z;$		$2556 = -x, \frac{1}{2} + y, 1-z$					

Table 5. The geometry of the intermolecular hydrogen bonds in **3j**.

# **CONCLUSIONS**

Investigation studies on the reactions of α-hydroxycarboxylic acid hydrazides and orthoesters in different conditions revealed the possibility to synthesize both acyclic and heterocyclic compounds. Hydrazides heated in the excess of orthoesters gave acyclic 1-(alkanecarbonyl)-2-ethoxymethylenehydrazines (**2**) while in the presence of ethanol and acetic acid the more extended *N,N'*-bis-(alkanecarbonylamino)formamidines (**4**) were formed. The lasts underwent cyclization to 4-acylamino-1,2,4-triazoles (**5**). Those cases where reactions were carried only in acetic acid medium and without the presence of alcohol, two different heterocyclic products were formed, the derivatives of 6-phenyl-1,3,4-oxadiazin-5(*6H*)-one (**3**) and 2-hydroxymethyl-1,3,4-oxadiazole (**6**). Concluding, α-hydroxyacid hydrazides can constitute potential precursors for the synthesis of nitrogen- and nitrogen-oxygen-containing heterocyclic systems.

# **EXPERIMENTAL**

UV spectra were recorded on a Shimadzu UV-2102 spectrophotometer. Elemental analyses were carried out with a VarioEL analyser. The  ${}^{1}$ H- and  ${}^{13}$ C-NMR spectra were recorded on a Varian Inova 300 spectrometer in DMSO solution using TMS as internal standard. Thin layer chromatography was carried out on silica gel 60 F<sub>254</sub> (Merck) thin layer chromatography plates using a benzene-ethyl acetate (1:3 v/v) as the mobile phase. Optical rotations were measured on Perkin Elmer Polarymeter 141 in methanol solution at the concentration of approx. 1 % (D line of sodium light, room temperature). Orthoesters were purchased from Fluka Chemie GmbH and methyl esters of benzilic, *S*- and *R*-mandelic acids from Alfa Aesar  $Gmhh&Co$  K $G$ .

# **Synthesis of** α**-hydroxyacids hydrazides (1a-c).**

The hydrazides of  $\alpha$ -hydroxyacids were obtained according to a standard procedure in the reaction of methyl esters of  $\alpha$ -hydroxyacids with hydrazine hydrate.

The hydrazide of *S*-mandelic acid  $(1a)^{22}$ : mp 151-153<sup>o</sup>C;  $[\alpha]_D^{20}$ +38.2 (MeOH, C=1.0). The hydrazide of *R*-mandelic acid  $(1b)^{22}$ : mp 152-153<sup>o</sup>C; [ $\alpha$ ]<sub>D</sub><sup>20</sup>-38.1 (MeOH, C=1.0). The hydrazide of benzilic acid  $(1c)^{23}$ : mp 167-169<sup>o</sup>C.

# **General procedure for the preparation of substituted of 1,3,4-oxadiazin-5(***6H***)-ones (3) and 2-(1-hydroxy-1-phenylmethyl)-1,3,4-oxadiazoles (6).**

The starting hydrazide (0.01 mole) of benzilic (**1a**) or mandelic acids (**1b**, **1c**) was added to the mixture of the appropriate triethyl orthoester (0.05 mole) and 1 mL (0.018 mole) of glacial AcOH. It was kept under reflux for about 3 h. After cooling the excessive orthoester and AcOH were evaporated under reduced pressure. The crude yellow oil was washed with 50 mL of hot water, dissolved in 50 mL of  $Et<sub>2</sub>O$  and dried over anhydrous CaCl<sub>2</sub>. The solvent was evaporated and the oily residue was subjected to the column chromatography (silica gel, eluent: benzene-AcOEt 1:3 mixture). Products (**3**, **6**) were crystallized from benzene-hexane mixtures.

Products obtained from benzilic acid hydrazide:

*6,6-Diphenyl-1,3,4-oxadiazin-5(6H)-one* (**3a**).

This compound was obtained as a white solid in 65% yield; mp 212-214°C; R<sub>f</sub>: 0.62; <sup>1</sup>H-NMR (DMSO- $d_6$ , Me<sub>4</sub>Si): δ 7.29-7.43 (m, 11H, 2 Ph, CH), 11.24 (s, 1H, NH) ppm; <sup>13</sup>C-NMR: δ 83.74 (C6), 127.02, 128.33, 128.74, 138.24 (Ph), 141.54 (C2), 162.68 (C5) ppm; MS: *m/z* (int %) 51 (14), 63 (17), 77 (34), 78 (12), 82 (12), 103 (22), 105 (37), 164 (10), 165 (80), 166 (51), 167 (15), 193 (18), 194 (100), 195 (15), 252 (M<sup>+</sup>, 11); UV:  $\lambda_{max}(\epsilon \cdot 10^{-3})$  MeOH 244.0 (3.40), 208.2 (17.25). *Anal.* Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 71.41; H, 4.80; N, 11.10. Found: C, 71.45; H, 4.83; N, 11.11.

*2-(1,1-Diphenyl-1-hydroxymethyl)-1,3,4-oxadiazole* (**6a**).

This compound was obtained as a white solid in 25% yield; mp 208-210°C; R<sub>f</sub>: 0.34; <sup>1</sup>H-NMR (DMSO-*d6*, Me4Si): δ 7.05 (s, 1H, OH), 7.30-7.44 (m, 10H, 2 Ph), 10.07 (s, 1H, H-C5) ppm; 13C-NMR: δ 80.42 (COH), 127.36, 127.62, 143.69 (Ph), 157.70 (C5), 167.98 (C2) ppm; MS: *m/z* (int %) 51 (12), 77 (15), 105 (100), 165 (62), 181 (18), 181 (72), 183 (15), 194 (85), 252 ( $M^+$ , 24); UV:  $\lambda_{max}(\epsilon \cdot 10^{-3})$  MeOH 255.0 (0.54), 206.0 (21.60). *Anal.* Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 71.41; H, 4.80; N, 11.10. Found: C, 71.42; H, 4.79; N, 11.08.

*6,6-Diphenyl-2-methyl-1,3,4-oxadiazin-5(6H)-one* (**3b**).

This compound was obtained as a white solid in 21% yield; mp 185-187°C; R<sub>f</sub>: 0.55; <sup>1</sup>H-NMR (DMSO-*d6*, Me4Si): δ 2.01 (s, 1H, CH3), 7.29-7.45 (m, 10H, 2 Ph), 11.09 (s, 1H, NH) ppm; 13C-NMR: δ

18.15 (CH3), 83.64 (C6), 126.88, 128.35, 128.65, 138.64 (Ph), 149.98 (C2), 162.40 (C5) ppm; MS: *m/z* (int %) 77 (10), 165 (64), 166 (66), 167 (12), 194 (100), 195 (16), 266 (M<sup>+</sup>, 14); UV:  $\lambda_{\text{max}}(\epsilon \cdot 10^{-3})$  MeOH 243.6 (4.15), 206.4 (20.71). *Anal.* Calcd for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 71.16; H, 5.31; N, 10.53. Found: C, 72.20; H, 5.30; N, 10.53.

*2-(1,1-Diphenyl-1-hydroxymethyl)-5-methyl-1,3,4-oxadiazole* (**6b**).

This compound was obtained as a white solid in 68% yield; mp 191-193 $^{\circ}$ C<sup>22</sup>; R<sub>f</sub>: 0.42; <sup>1</sup>H-NMR (DMSO-*d6*, Me4Si): δ 2.50 (s, 3H, CH3), 7.29-7.37 (m, 11H, 2 Ph, OH) ppm; 13C-NMR: δ 10.59 (CH3), 75.95 (COH), 126.64, 127.66, 127.98, 143.60 (Ph), 164.36 (C5), 169.10 (C2) ppm; MS: *m/z* (int %) 51 (22), 77 (46), 105 (100), 181 (15), 182 (60), 183 (11), 189 (10), 266 ( $M^+$ , 28); UV:  $\lambda_{max} (\epsilon \cdot 10^{-3})$  MeOH 258.0 (0.52), 206.2 (22.54). *Anal.* Calcd for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 71.16; H, 5.31; N, 10.53. Found: C, 72.18; H, 5.35; N, 10.50.

*6,6-Diphenyl-2-ethyl-1,3,4-oxadiazin-5(6H)-one* (**3c**).

This compound was obtained as a white solid in 15% yield; mp 125-127°C; R<sub>f</sub>: 0.48; <sup>1</sup>H-NMR (DMSO-*d6*, Me4Si): 0.98 (t, *J*=7.5 Hz, 3H, CH3), 2.31 (q, *J*=7.5 Hz, 2H, CH2), 7.28-7.42 (m, 10H, 2 Ph), 11.12 (s, 1H, NH) ppm; <sup>13</sup>C-NMR; δ 10.52 (CH<sub>3</sub>), 18.47 (CH<sub>2</sub>), 83.56 (C6), 126.78, 128.45, 128.71, 138.77 (Ph), 153.12 (C2), 162.45 (C5) ppm; MS: *m/z* (int %) 77 (15), 165 (49), 166 (56), 194 (100), 195 (13), 280 (M<sup>+</sup>, 27); UV:  $\lambda_{max}(\epsilon \cdot 10^{-3})$  MeOH 252.0 (5.06), 202.8 (24.56). *Anal*. Calcd for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>: C, 72.83; H, 5.76; N, 9.99. Found: C, 72.82; H, 5.80; N, 10.01.

*2-(1,1-Diphenyl-1-hydroxymethyl)-5-ethyl-1,3,4-oxadiazole* (**6c**).

This compound was obtained as a white solid in 78% yield; mp 121-123°C; R<sub>f</sub>: 0.52; <sup>1</sup>H-NMR (DMSO-*d6*, Me4Si): 1.24 (t, *J*=7.5 Hz, 3H, CH3), 2.84 (q, *J*=7.5 Hz, 2H, CH2), 7.27-7.36 (m, 11H, Ph, OH) ppm; <sup>13</sup>C-NMR: δ 10.44 (CH<sub>3</sub>), 18.35 (CH<sub>2</sub>), 75.98 (COH), 126.60, 127.63, 127.95, 143.58 (Ph), 168.15 (C5), 168.95 (C2) ppm; MS: *m/z* (int %) 51 (18), 54 (10), 77 (45), 105 (100), 165 (15), 181 (16), 182 (53), 183 (15), 193 (16), 280 (M<sup>+</sup>, 49); UV: λ<sub>max</sub> (ε·10<sup>-3</sup>) MeOH 259.0 (0.51), 206.0 (24.20). *Anal.* Calcd for  $C_{17}H_{16}N_2O_2$ : C, 72.83; H, 5.76; N, 9.99. Found: C, 72.85; H, 5.71; N, 9.96.

*2-(1,1-Diphenyl-1-hydroxymethyl)-5-phenyl-1,3,4-oxadiazole* (**6d**).

This compound was obtained as a white solid in 85% yield; mp 151-153°C; R<sub>f</sub>: 0.60; <sup>1</sup>H-NMR (DMSO-*d6*, Me4Si): 7.29-7.46 (m, 10H, 2 Ph), 7.53 (s, 1H, OH), 7.59-7.64 (m, 3H, Ph-C5), 7.99 (d, 2H, Ph-C5) ppm; 13C-NMR: δ 76.15 (COH), 123.18, 126.58, 126.64, 127.73, 128.03, 129.49, 132.15, 143.46 (Ph), 164.49 (C5), 169.18 (C2) ppm; MS: *m/z* (int %) 77 (56), 103 (17), 105 (100), 182 (18), 223 (14), 251 (11), 311 (18), 328 (M<sup>+</sup>, 12); UV:  $\lambda_{\text{max}}(\epsilon \cdot 10^{-3})$  MeOH 252.8 (25.57), 207.0 (44.00). *Anal.* Calcd for  $C_{21}H_{16}N_2O_2$ : C, 76.80; H, 4.92; N, 8.52. Found: C, 76.83; H, 4.94; N, 8.50.

Products obtained from (*S*)-mandelic acid hydrazide:

*6-Phenyl-1,3,4-oxadiazin-5(6H)-one* (**3e**).

This compound was obtained as a white solid in 50% yield; mp 129-132°C; R<sub>f</sub>: 0.54;  $\left[\alpha\right]_D^2$ <sup>0</sup> –203.9 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, Me<sub>4</sub>Si): δ 5.79 (s, 1H, H-C6), 7.25 (s, 1H, H-C2), 7.35-7.44 (m, 5H, Ph), 11.00 (s, 1H, H-N4) ppm; 13C-NMR: δ 75.63 (C6), 126.42, 127.11, 128.80, 135.93 (Ph), 140.40 (C2), 161.21 (C5) ppm; MS: *m/z* (int %) 63 (10), 77 (14), 79 (10), 89 (17), 90 (45), 118 (100), 119 (10), 176 (M<sup>+</sup>, 11); UV:  $\lambda_{\text{max}} (\epsilon \cdot 10^{-3})$  MeOH 247.2 (2.88), 207.8 (7.78). *Anal*. Calcd for C<sub>9</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>: C, 61.35; H, 4.58; N, 15.89. Found: C, 61.30; H, 4.65; N, 15.82.

*(2S)-(1-Hydroxy-1-phenylmethyl)-1,3,4-oxadiazole* (**6e**).

This compound was obtained as a colourless oil in 45% yield;  $R_f$ : 0.40;  $[\alpha]_D^{20}$  +4.2 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, Me<sub>4</sub>Si): δ 6.08 (d, 1H, *J*=4.5 Hz, H-C2), 6.76 (d, 1H, *J*=4.5 Hz, OH), 7.32-7.46 (m, 5H, Ph), 9.17 (s, 1H, H-C5) ppm; 13C-NMR: δ 66.08 (H**C**OHPh), 126.41, 127.29, 128.42, 139.51 (Ph), 154.73 (C5), 167.02 (C2) ppm; MS: *m/z* (int %) 71 (28), 77 (68), 78 (21), 79 (48), 90 (12), 105 (100), 106 (34), 107 (20), 118 (10), 132 (11), 176 ( $M^+$ , 44); UV:  $\lambda_{max}$  ( $\varepsilon$ ·10<sup>-3</sup>) MeOH 257.4 (0.26), 210.2 (8.39). *Anal.* Calcd for C<sub>9</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>: C, 61.35; H, 4.58; N, 15.89. Found: C, 61.34; H, 4.60; N, 15.86.

*2-Methyl-(6S)-phenyl-1,3,4-oxadiazin-5(6H)-one* (**3f**).

This compound was obtained as a white solid in 45% yield; mp 106-108°C; R<sub>f</sub>: 0.40;  $[\alpha]_D^{20}$  - 117.8 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, Me<sub>4</sub>Si): 1.95 (s, 3H, CH<sub>3</sub>), 5.75 (s, 1H, H-C6), 7.35-7.46 (m, 5H, Ph), 10.89 (s, 1H, H-N4) ppm; 13C-NMR: δ 17.84 (CH3), 75.73 (C6), 126.94, 127.40, 128.65, 135.98 (Ph), 148.69 (C2), 160.87 (C5) ppm; MS: *m/z* (int %) 63 (10), 77 (11), 89 (13), 90 (39), 105 (10), 118 (100), 119 (10), 190 (M<sup>+</sup>, 11); UV:  $\lambda_{max} (\epsilon \cdot 10^{-3})$  MeOH 245.0 (4.30), 207.8 (9.87). *Anal*. Calcd for C<sub>10</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>: C, 63.14; H, 5.31; N, 14.72. Found: C, 63.19; H, 5.37; N, 14.70.

*(2S)-(1-Hydroxy-1-phenylmethyl)-5-methyl-1,3,4-oxadiazole* (**6f**).

This compound was obtained as a white solid in 50% yield; mp 126-128°C; R<sub>f</sub>: 0.32;  $[\alpha]_D^{20}$ +5.7 (MeOH, C=1.0); <sup>1</sup> H-NMR (DMSO-*d6*, Me4Si): δ 2.45 (s, 3H, CH3), 5.96 (d, *J*=4.8 Hz, 1H, **H**COHPh), 6.67 (d, *J*=4.8 Hz, 1H, HC**OH**Ph), 7.29-7.47 (m, 5H, Ph) ppm; 13C-NMR: δ 10.46 (CH3), 66.26 (H**C**OHPh), 126.40, 128.08, 128.40, 139.52 (Ph), 164.05 (C5), 167.23 (C2) ppm; MS: *m/z* (int %) 77 (66), 78 (17), 79 (50), 85 (15), 91 (11), 105 (100), 106 (22), 107 (16), 132 (10), 190 ( $M^+$ , 36); UV:  $\lambda_{max} (\epsilon \cdot 10^{-3})$  MeOH 257.2 (0.18), 207.8 (10.34). *Anal.* Calcd for C<sub>10</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>: C, 63.14; H, 5.31; N, 14.72. Found: C, 63.16; H, 5.35; N, 14.76.

*2-Ethyl-(6S)-phenyl-1,3,4-oxadiazin-5(6H)-one* (**3g**).

This compound was obtained as a colourless oil in 24% yield;  $R_f$ : 0.50;  $[\alpha]_D^{20}$ -50.5 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-*d<sub>6</sub>*, Me<sub>4</sub>Si): δ 0.96 (t, *J*=7.5 Hz, 3H, CH<sub>3</sub>), 2.23 (q, *J*=7.5 Hz, 2H, CH<sub>2</sub>), 5.73 (s, 1H, H-C6), 7.24-7.42 (m, 5H, Ph), 10.98 (s, 1H, NH) ppm; 13C-NMR: δ 9.82 (CH3), 18.20 (CH2), 75.63 (C6), 127.05, 128.22, 128.72, 135.92 (Ph), 151.95 (C2), 161.00 (C5) ppm; MS: *m/z* (int %) 77 (24), 79 (11), 89

 $(17)$ , 90  $(40)$ , 91  $(21)$ , 105  $(29)$ , 117  $(13)$ , 118  $(100)$ , 119  $(12)$ , 131  $(12)$ , 132  $(19)$ , 204  $(M<sup>+</sup>, 19)$ ; UV:  $\lambda$  $_{max}$  (ε·10<sup>-3</sup>) MeOH 257.4 (0.18), 209.4 (10.62). *Anal.* Calcd for C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 64.68; H, 5.93; N, 13.71. Found: C, 64.62; H, 5.92; N, 13.73.

*(2S)-(1-Hydroxy-1-phenylmethyl)-5-ethyl-1,3,4-oxadiazole* (**6g**).

This compound was obtained as a white solid in 64% yield; mp 69-71°C; R<sub>f</sub>: 0.32; [ $\alpha$ ]<sub>D</sub><sup>20</sup>+18.5 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-*d<sub>6</sub>*, Me<sub>4</sub>Si): δ 1.21 (t, *J*=7.5 Hz, 3H, CH<sub>3</sub>), 2.81 (q, *J*=7.5 Hz, 2H, CH<sub>2</sub>), 5.98 (d, *J*=5.1 Hz, 1H, **H**COHPh), 6.60 (d, *J*=5.1 Hz, 1H, HC**OH**Ph), 7.25-7.46 (m, 5H, Ph) ppm; 13C-NMR: δ 10.37 (CH3), 18.27 (CH2), 66.35 (H**C**OHPh), 126.43, 128.05, 128.38, 139.58 (Ph), 167.14 (C5), 167.87 (C2) ppm; MS: *m/z* (int %) 71 (12), 77 (70), 78 (16), 79 (55), 91 (11), 97 (22), 99 (13), 105 (100), 106 (20), 107 (24), 118 (10), 132 (12), 204 ( $M^+$ , 28); UV:  $\lambda_{max}$  ( $\varepsilon$ ·10<sup>-3</sup>) MeOH 251.4 (0.23), 207.4 (9.68). *Anal.* Calcd for C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 64.68; H, 5.93; N, 13.71. Found: C, 64.65; H, 5.98; N, 13.75.

*(2S)-(1-Hydroxy-1-phenylmethyl)-5-phenyl-1,3,4-oxadiazole* (**6h**).

This compound was obtained as a white solid in 85% yield; mp 148-149°C; R<sub>f</sub>: 0.45; [ $\alpha$ ]<sub>D</sub><sup>20</sup>+60.2 (MeOH, C=1.0); <sup>1</sup> H-NMR (DMSO-*d6*, Me4Si): δ 6.13 (d, *J*=4.8 Hz, 1H, **H**COHPh), 6.90 (d, *J*=4.8 Hz, 1H, HC**OH**Ph), 7.32-7.46 (m, 3H, Ph), 7.56-7.64 (m, 5H, Ph), 7.98 (d, *J*=6.6 Hz, 2H, Ph) ppm; 13C-NMR: δ 66.44 (H**C**OHPh), 123.16, 126.51, 126.58, 128.19, 128.47, 129.48, 132.10, 139.43 (2 Ph), 164.23 (C5), 167.46 (C2) ppm; MS: *m/z* (int %) 63 (11), 76 (11), 77 (100), 78 (11), 79 (38), 103 (24), 104 (17), 105 (96), 106 (17), 107 (37), 145 (15), 252 (M<sup>+</sup>, 41); UV:  $\lambda_{\text{max}} (\epsilon \cdot 10^{-3})$  MeOH 252.0 (19.26), 204.6 (25.04). *Anal.* Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 71.41; H, 4.80; N, 11.10. Found: C, 71.45; H, 4.83; N, 11.13.

Products obtained from (*R*)-mandelic acid hydrazide:

*(2R)-(1-Hydroxy-1-phenylmethyl)-1,3,4-oxadiazole* (**6i**).

This compound was obtained as a colourless oil in 32% yield; R<sub>f</sub>: 0.40;  $[\alpha]_D^2$  -4.3 (MeOH, C=1.0); 1 H-NMR (DMSO-*d6*, Me4Si): δ 6.08 (d, 1H, *J*=4.5 Hz, H-C2), 6.78 (d, 1H, *J*=4.5 Hz, OH), 7.30-7.50 (m, 5H, Ph), 9.19 (s, 1H, H-C5) ppm; 13C-NMR: 66.31 (H**C**OHPh), 126.49, 127.84, 128.36, 139.50 (Ph), 154.75 (C5), 167.10 (C2) ppm; MS: *m/z* (int %) 71 (18), 77 (60), 78 (11), 79 (40), 90 (22), 105 (100), 106 (24), 107 (12), 118 (11), 132 (18), 176 ( $M^+$ , 40); UV:  $\lambda_{max}$  ( $\varepsilon$ ·10<sup>-3</sup>) MeOH 241.2 (0.49), 209.4 (8.29). *Anal.* Calcd for C<sub>9</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>: C, 61.35; H, 4.58; N, 15.89. Found: C, 61.32; H, 4.62; N, 15.90.

*2-Methyl-(6R)-phenyl-1,3,4-oxadiazin-5(6H)-one* (**3j**).

This compound was obtained as a white solid in 50% yield; mp 103-105°C; R<sub>f</sub>: 0.40;  $[\alpha]_D^{20} + 119.3$ (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, Me<sub>4</sub>Si): 1.96 (s, 3H, CH<sub>3</sub>), 5.73 (s, 1H, H-C6), 7.35-7.40 (m, 5H, Ph), 10.90 (s, 1H, H-N4) ppm; <sup>13</sup>C-NMR: δ 17.68 (CH<sub>3</sub>), 75.70 (C6), 126.64, 127.26, 128.58, 135.90 (Ph), 148.71 (C2), 160.85 (C5) ppm; MS: *m/z* (int %) 77 (12), 89 (13), 90 (39), 105 (11), 118 (100), 119 (10), 190 (M<sup>+</sup>, 11); UV:  $\lambda_{\text{max}} (\epsilon \cdot 10^{-3})$  MeOH 245.8 (4.25), 210.4 (9.62). *Anal*. Calcd for C<sub>10</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>: C, 63.14;

H, 5.31; N, 14.72. Found: C, 63.20; H, 5.35; N, 14.68.

*(2R)-(1-Hydroxy-1-phenylmethyl)-5-methyl-1,3,4-oxadiazole* (**6j**).

This compound was obtained as a white solid in 45% yield; mp 126-127°C; R<sub>f</sub>: 0.32; [ $\alpha$ ]<sub>D</sub><sup>20</sup>-5.7 (MeOH, C=1.0); <sup>1</sup> H-NMR (DMSO-*d6*, Me4Si): δ 2.44 (s, 3H, CH3), 5.94 (d, *J*=4.8 Hz, 1H, **H**COHPh), 6.63 (d, *J*=4.8 Hz, 1H, HC**OH**Ph), 7.33-7.44 (m, 5H, Ph) ppm; 13C-NMR: δ 10.46 (CH3), 66.94 (H**C**OHPh), 127.08, 128.75, 129.07, 139.64 (Ph), 163.50 (C5), 167.81 (C2) ppm; MS: *m/z* (int %) 77 (45), 78 (14), 79 (51), 85 (10), 91 (17), 105 (100), 106 (21), 107 (19), 190 ( $M^+$ , 42); UV:  $\lambda_{max} (\epsilon \cdot 10^{-3})$  MeOH 257.2 (0.20), 209.0 (7.76). *Anal.* Calcd for C<sub>10</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>: C, 63.14; H, 5.31; N, 14.72. Found: C, 63.17; H, 5.33; N, 14.70.

*2-Ethyl-(6R)-phenyl-1,3,4-oxadiazin-5(6H)-one* (**3k**).

This compound was obtained as a colourless oil in 30% yield;  $R_f$ : 0.50;  $[\alpha]_D^{20}$  +48.4 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-*d<sub>6</sub>*, Me<sub>4</sub>Si): δ 0.96 (t, *J*=7.5 Hz, 3H, CH<sub>3</sub>), 2.23 (q, *J*=7.5 Hz, 2H, CH<sub>2</sub>), 5.72 (s, 1H, H-C6), 7.31-7.42 (m, 5H, Ph) ppm; 10.96 (s, 1H, NH) ppm; <sup>13</sup>C-NMR:  $\delta$  9.84 (CH<sub>3</sub>), 18.27 (CH<sub>2</sub>), 75.73 (C6), 127.09, 128.26, 128.73, 135.99 (Ph), 151.98 (C2), 161.06 (C5) ppm; MS: *m/z* (int %) 77 (20), 89 (11), 90 (30), 91 (13), 105 (19), 118 (100), 119 (15), 132 (24), 204 ( $M^+$ , 29); UV:  $\lambda_{max} (\epsilon \cdot 10^{-3})$  MeOH 248.2 (2.74), 209.4 (9.39). *Anal.* Calcd for C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 64.68; H, 5.93; N, 13.71. Found: C, 64.64; H, 5.90; N, 13.75.

*(2R)-(1-Hydroxy-1-phenylmethyl)-5-ethyl-1,3,4-oxadiazole* (**6k**).

This compound was obtained as a white solid in 65% yield; mp 68-70°C; R<sub>f</sub>: 0.32; [ $\alpha$ ]<sub>D</sub><sup>20</sup>-18.6 (MeOH, C=1.0); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, Me<sub>4</sub>Si): δ 1.20 (t, *J*=7.5 Hz, 3H, CH<sub>3</sub>), 2.81 (q, *J*=7.5 Hz, 2H, CH<sub>2</sub>), 5.96 (d, *J*=5.1 Hz, 1H, **H**COHPh), 6.58 (d, *J*=5.1 Hz, 1H, HC**OH**Ph), 7.27-7.46 (m, 5H, Ph) ppm; 13C-NMR: δ 11.06 (CH3), 18.94 (CH2), 66.92 (H**C**OHPh), 127.08, 128.70, 129.04, 140.29 (Ph), 167.83 (C5), 166.52 (C2) ppm; MS:  $m/z$  (int %) 77 (57), 78 (11), 79 (34), 91 (19), 97 (16), 99 (12), 105 (100), 106 (12), 107 (34), 132 (15), 204 ( $M^+$ , 38); UV:  $\lambda_{max}$  ( $\varepsilon$ ·10<sup>-3</sup>) MeOH 257.4 (0.26), 210.8 (9.89). *Anal.* Calcd for C11H12N2O2: C, 64.68; H, 5.93; N, 13.71. Found: C, 64.70; H, 5.95; N, 13.70.

*(2,6R)-Diphenyl-1,3,4-oxadiazin-5(6H)-one* (**3l**).

This compound was obtained as a white solid in 10% yield; mp 83-84°C; R<sub>f</sub>: 0.12; [ $\alpha$ ]<sub>D</sub><sup>20</sup>-28.1 (MeOH, C=1.0); <sup>1</sup> H-NMR (DMSO-*d6*, Me4Si): 6.04 (s, 1H, H-C6), 7.28-7.70 (m, 8H, Ph-C6, Ph-C2), 7.79 (d, *J*=8.1 Hz, 2H, Ph-C2), 11.44 (s, 1H, NH) ppm; <sup>13</sup>C-NMR: δ 75.95 (C6), 125.97, 126.62, 127.63, 128.21, 128.70, 128.89, 135.39, 136.76 (2 Ph), 147.00 (C2), 161.50 (C5) ppm; MS: *m/z* (int %) 77 (49), 90 (18), 91 (11), 105 (100), 118 (53), 252 (M<sup>+</sup>, 14); UV:  $\lambda_{\text{max}}(\epsilon \cdot 10^{-3})$  MeOH 276.8 (10.78), 203.2 (23.51). *Anal*. Calcd for  $C_{15}H_{12}N_2O_2$ : C, 71.41; H, 4.80; N, 11.10. Found: C, 71.38; H, 4.85; N, 11.15.

# *(2R)-(1-Hydroxy-1-phenylmethyl)-5-phenyl-1,3,4-oxadiazole* (**6l**).

This compound was obtained as a white solid in 84% yield; mp 148-149°C; R<sub>f</sub>: 0.45; [ $\alpha$ ]<sub>D</sub><sup>20</sup>-60.4 (MeOH, C=1.0); <sup>1</sup> H-NMR (DMSO-*d6*, Me4Si): δ 6.15 (d, *J*=4.8 Hz, 1H, **H**COHPh), 6.89 (d, *J*=4.8 Hz, 1H, HC**OH**Ph), 7.32-7.44 (m, 3H, Ph), 7.53-7.62 (m, 5H, Ph), 7.99 (d, *J*=6.6 Hz, 2H, Ph) ppm; 13C-NMR: δ 66.40 (H**C**OHPh), 123.26, 126.58, 126.70, 128.98, 129.45, 129.98, 132.95, 139.98 (2 Ph), 164.43 (C5), 167.62 (C2) ppm; MS: *m/z* (int %) 77 (100), 78 (16), 79 (45), 103 (14), 105 (66), 106 (21), 107 (38), 145 (11), 252 (M<sup>+</sup>, 26); UV: λ<sub>max</sub> (ε·10<sup>-3</sup>) MeOH 254.4 (20.02), 204.2 (26.05). *Anal*. Calcd for  $C_{15}H_{12}N_2O_2$ : C, 71.41; H, 4.80; N, 11.10. Found: C, 71.46; H, 4.82; N, 11.15.

**X-Ray structure determination for 3j:**  $C_{10}H_{10}N_2O_2$ ,  $M = 190.20$ , monoclinic, space group P<sub>21</sub>, a = 8.4439(17) Å, b = 5.8484(12) Å, c = 19.938(4) Å,  $\beta$  = 95.07(3)<sup>o</sup>, V = 980.7(3) Å<sup>3</sup>, Z = 4, D<sub>x</sub> = 1.288 gcm<sup>-3</sup>, F(000) = 400,  $\mu$ (CuK $\alpha$ ) = 0.758 mm<sup>-1</sup>, crystal size 0.50 x 0.05 x 0.05 mm. Colorless needle crystals were obtained by slow evaporation of a methanol solution. X-Ray data were collected on a Bruker SMART APEX CCD diffractometer at rt. Lattice parameters were obtained from least-squares refinement of setting angles of 48 reflections (θ range  $10.1 - 39.2^{\circ}$ ). Intensity data were collected using CuKa radiation ( $\lambda = 1.54178$  Å), ω-scan technique, multi-scan absorption correction<sup>24</sup> (T<sub>min</sub>/T<sub>max</sub> = 0.8081); no. of measured reflection 11173 ( $\theta$  range 2.22 – 70.05°, index ranges -10  $\le h \le 10$ , -6  $\le k \le 6$ ,  $-24 \le l \le 24$ ), no. of independent reflections 3412 ( $R_{int} = 0.0158$ ). The structure was solved by direct methods using  $SIR92^{25}$  and refined by full-matrix least-squares with  $SHELXL97<sup>26</sup>$  All hydrogen atoms were located from ∆ρ map and their coordinates were refined with isotropic displacement parameters taken as 1.5 times those of the respective parent atoms. The assumed absolute stereochemistry of the **3j** was confirmed by refinement of the Flack parameter <sup>26</sup> x = -0.3(2) with 1359 Bijvoet pairs. The final R = 0.0420, wR = 0.1251 for 1251 reflections  $[I > 2\sigma(I)]$  and 314 parameters, S = 0.944, extinction coefficient  $g = 0.0068(12)$ ,  $(\Delta/\sigma)_{max} = 0.000$ ,  $(\Delta \rho)_{max} = 0.257$  and  $(\Delta \rho)_{min} = -0.194$  eÅ<sup>-3</sup>.

### **ACKNOWLEDGEMENTS**

The authors wish to thank crystallographers: Andrzej Fruziński, Ph.D. from Technical University of Lodz and Zbigniew Karczmarzyk, Ph.D. from University of Podlasie for X-Ray analysis. This work was supported by the State Committee of Scientific Research, Grant No 3T09B01929.

### REFERENCES

- 1. A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, Comprehensive Heterocyclic Chemistry II, Elsevier Science Ltd., Oxford, 1996, vol. 6, 739.
- 2. I. Mikhailow, I. Gagov, A. Toskov, D. Gregoriev, and L. Dryanovska-Noninska, *Acta*

*Microbiol. Bulg.*, 1984, **14**, 124 (*Chem. Abstr*., 1984, **101**, 163 258).

- 3. Yu. G. Atanasova and A. G. Atanasov, *Dokl. Bulg. Akad. Nauk*, 1990, **43**, 107 (*Chem. Abstr*., 1990, **115**, 21 673).
- 4. J. Mihailov, A. E. Hristov, and V. Abadjieeff, *Dokl. Bulg. Akad. Nauk*, 1992, **45**, 109 (*Chem. Abstr*., 1993, **119**, 266 274).
- 5. K. Suhasini, T. V. P. Rao, and V. Trirupathiaiah, *Current Sci.,* 1983, **52**, 1133.
- 6. F. Mazouz, L. Lebreton, R. Milcent, and C. Burstein, *Eur. J. Med. Chem.,* 1988, **23**, 441.
- 7. J. L. Malleron, D. Mansuy, N. T. Vuong, and D. Varech, *Eur. Pat.* 410 834 (1991) (*Chem. Abstr*., 1991, **115**, 183366).
- 8. W. J. Coates, *Eur. Pat.* 220 044 (1987) (*Chem. Abstr*., 1988, **108**, 112 503).
- 9. A. Mertens, W. G. Friebe, B. Müller-Beckmann, W. Kampe, L. Kling, and W. Von der Saal, *J. Med. Chem.*, 1990, **33**, 2870.
- 10. M. A. Dekeyser and R. C. Moore, *US Pat.* 5 010 068 (1991) (*Chem. Abstr*., 1991, **115**, 114776).
- 11. M. A. Dekeyser, P. T. McDonald, G. W. Angle Jr., and R. G. H. Downer, *J. Agric. Food Chem.,* 1993, **41**, 1329 (*Chem. Abstr*., 1993, **119**, 88868).
- 12. W. Zieliński, A.Kudelko, and W. Czardybon, *J. Heterocycl. Chem*., 2005, **42**, 1393.
- 13. D. L.Trepanier and V. Sprancmanis, *J. Org. Chem*., 1964, **29**, 673.
- 14. T. Taguchi, J. Ishibashi, T. Matsuo, and M. Kojima, *J. Org. Chem*., 1964, **29**, 1097.
- 15. A. J. Elliot, *Can. J. Chem*., 1973, **51**, 4115.16. E. Koerner von Gustorf, D. V. White, B. Kim, D. Hess, and J. Leitich, *J. Org. Chem*., 1970, **35**, 1155.
- 16. J. H. Hall and M. Wojciechowska, *J. Org. Chem*., 1978, **43**, 4869.
- 17. E. C. Taylor, H. M. L. Davis, and W. T. Lavell, *J. Org. Chem*., 1984, **49**, 2204.
- 18. R. M. Wilson and T. J. Chow, *Tetrahedron Lett*., 1983, **24**, 4635.
- 19. L. J. Farrugia, *J. Appl. Cryst.,* 1997, **30**, 565.
- 20. W. L. Duax and D. A. Norton, 'Atlas of Steroid Structures,' Vol. 1, New York: Plenum Press, 1975, pp. 16-19.
- 21. E. M. Luis and A. McKenzie, *J. Chem. Soc*., 1941, **98**, 647.
- 22. H. Aspelund, Acta Acad. Aboensis Math. at Phys. 6, 1932, **12**, 8.
- 23. G. M. Sheldrick, SADABS ver. 2.06, University of Göttingen, Germany, 2002.
- 24. A. Altomare, G. Cascarano, C. Giacovazzo, and A. Guagliardi, *J. Appl. Cryst*., 1993, **26**, 343.
- 25. G. M. Sheldrick, SHELXL97, Program for the Refinement of Crystal Structures: University of Göttingen, Germany, 1997.
- 26. H. D. Flack, *Acta Crystallogr.*, 1983, **A39**, 876.